Podcasts Answers from the Lab

Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.

Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions involved with treating kidney disease.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the latest monkeypox developments, potential scenarios for monkeypox moving forward, and where the VALID Act stands.

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.

This week on "Answers From the Lab," William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss how monkeypox can be transmitted, the possibilities of a future Emergency Use Authorization (EUA), and access to testing.

John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a condition that can lead to kidney failure.

In this episode, Dr. Pritt and Dr. Morice discuss new developments in monkeypox testing, updates on the federal response, and lessons learned from managing other viruses.

Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.

John Osborn, operations administrator in the Department of Laboratory Medicine and Pathology at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D. about monkeypox testing. In this episode, John and Dr. Pritt discuss how Mayo Clinic swiftly operationalized monkeypox testing and the challenges involved with supporting the new assay, including staffing.

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the World Health Organization’s declaration of monkeypox as a global public health emergency, how Mayo Clinic Laboratories quickly implemented testing, and the public-private partnership to manage the response.

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

In this episode, Dr. Pritt and Dr. Morice discuss the science behind the increasing COVID-19 infections, why individuals can get reinfected with different variants, and the effectiveness of the at-home antigen tests.